Urs Wiedemann is a panelist on a workshop entitled “Let’s get personal: Advances in precision medicine are changing the way we identify and treat disease.”
CRA is a silver sponsor for this annual conference.
For more information on this event, click here.
An analysis of the effect of drug pricing provisions in the Build Back Better Act on pharmaceutical innovation
Charles River Associates has previously assessed the implications of proposals to implement international reference pricing in the US and found they would...